Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,160.50    6.00 (0.52%)
Bid:
1,162.50
Ask:
1,163.00
Spread: 0.50 (0.043%)
Market Cap: £9.85b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Admission to Trading

3 Jun 2026 10:35

RNS Number : 8554G
Smith & Nephew Plc
03 June 2026
 

Smith & Nephew plc

Admission to Trading

In accordance with the Financial Conduct Authority's Prospectus Rules: Admission to Trading on a Regulated Market sourcebook 1.5.2 and 1.5.3R, Smith & Nephew plc notifies the market that the following debt securities have been admitted to trading:

Issuer name:

 

Smith & Nephew plc

Issuer LEI:

 

213800ZTMDN8S67S1H61

Regulated market on which the securities have been admitted to trading:

 

Main Market of the London Stock Exchange plc

Name, type and ISIN of the securities:

 

EUR 500,000,000 4.250 per cent. Notes due 3 June 2038 (ISIN XS3384821834) issued under Smith & Nephew plc's U.S.$5,000,000,000 Euro Medium Term Note Programme

Number of securities admitted to trading:

 

EUR 500,000,000 in aggregate nominal amount

Date of admission to trading:

 

3 June 2026

 

Date of Prospectus relating to the securities:

Each of the base prospectus dated 17 March 2026 and the supplemental prospectus dated 15 May 2026 (together, the "Prospectus") under which the securities have been issued is available at:

 

https://smith-nephew.stylelabs.cloud/api/public/content/80866ebbfd2a42a797b41d878b374f70?v=a80c272c

 

https://smith-nephew.stylelabs.cloud/api/public/content/4fb968a0ffd1450b8ae4158c7069fbab?v=9f3a10c1

 

 

Final Terms available for viewing:

 

 

https://www.smith-nephew.com/en/who-we-are/investors#emtn-programme

 

 

For further information, please contact:

Investor contacts

Emily Heaven, Smith+Nephew +44 (0) 7811 919437

Craig Bijou, Smith+Nephew +1 (475) 850-8282

Media contacts

 

Charles Reynolds, Smith+Nephew +44 (0) 1923 477314

 

Disclaimer - Intended Addressees

Please note that the information contained in the Prospectus and the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus and the Final Terms is not addressed. Prior to relying on the information contained in the Prospectus or the Final Terms, you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ADMUPUWWQUPQUBW
Date   Source Headline
5th Jun 202612:12 pmRNSTransaction in Own Shares
4th Jun 20264:05 pmRNSDirector/PDMR Shareholding
3rd Jun 202611:21 amRNSDirector/PDMR Shareholding
3rd Jun 202610:35 amRNSAdmission to Trading
1st Jun 20263:10 pmRNSTotal Voting Rights
29th May 202610:37 amRNSTransaction in Own Shares
27th May 20269:31 amRNSPre Stabilisation Notice
22nd May 20261:32 pmRNSAdmission to Trading
22nd May 20269:58 amRNSTransaction in Own Shares
20th May 202611:25 amRNSDirector/PDMR Shareholding
19th May 20268:53 amRNSHolding(s) in Company
15th May 202612:28 pmRNSTransaction in Own Shares Replacement
15th May 202611:41 amRNSTransaction in Own Shares
14th May 20269:25 amRNSHolding(s) in Company
12th May 20264:03 pmRNSSterling Amount of Dividend
8th May 20267:00 amRNSShare Buyback Programme
6th May 20262:25 pmRNSResult of AGM
6th May 20267:00 amRNSSmith+Nephew First Quarter 2026 Trading Update
1st May 20261:10 pmRNSTotal Voting Rights
27th Apr 20267:00 amRNSExpert surgeons insights event for investors
22nd Apr 20268:46 amRNSNotice of Results
16th Apr 202611:12 amRNSDirector/PDMR Shareholding
15th Apr 20263:46 pmRNSDirector Declaration
14th Apr 20262:59 pmRNSReplacement: Annual Financial Report & AGM Notice
1st Apr 202612:23 pmRNSTotal Voting Rights
24th Mar 20264:16 pmRNSDirector/PDMR Shareholding
24th Mar 20268:45 amRNSHolding(s) in Company
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
16th Mar 20263:08 pmRNSAnnual Financial Report & Notice of AGM
10th Mar 20262:30 pmRNS-RSmith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
5th Mar 20267:30 amRNSDirector Declaration
2nd Mar 20261:36 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSFinal Results
5th Feb 202611:56 amRNSNotice of Results
2nd Feb 20264:00 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Feb 20263:05 pmRNSTotal Voting Rights
23rd Jan 20262:00 pmRNSDirector/PDMR Shareholding
21st Jan 20264:11 pmRNSCompletion of Acquisition
12th Jan 20264:30 pmRNSAcquisition of Integrity Orthopaedics
2nd Jan 202610:07 amRNSTotal Voting Rights
8th Dec 20257:00 amRNSNew Strategy and 2028 Financial Targets
1st Dec 20254:10 pmRNSTotal Voting Rights
19th Nov 202510:00 amRNSDirector/PDMR Shareholding
18th Nov 202510:18 amRNSHolding(s) in Company
12th Nov 20259:24 amRNSDirector/PDMR Shareholding
11th Nov 20254:40 pmRNSHolding(s) in Company
10th Nov 20251:46 pmRNSDirector/PDMR Shareholding
7th Nov 20259:38 amRNSDirector/PDMR Shareholding
7th Nov 20259:35 amRNSDirector/PDMR Shareholding
6th Nov 20257:01 amRNSDirectorate change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.